Running with Scissors: a Systematic Review of Substance Use and the Pre-exposure Prophylaxis Care Continuum Among Sexual Minority Men.

IF 4.4 2区医学 Q2 INFECTIOUS DISEASES Current HIV/AIDS Reports Pub Date : 2022-08-01 Epub Date: 2022-06-14 DOI:10.1007/s11904-022-00608-y

Michael Viamonte, Delaram Ghanooni, John M Reynolds, Christian Grov, Adam W Carrico

{"title":"Running with Scissors: a Systematic Review of Substance Use and the Pre-exposure Prophylaxis Care Continuum Among Sexual Minority Men.","authors":"Michael Viamonte, Delaram Ghanooni, John M Reynolds, Christian Grov, Adam W Carrico","doi":"10.1007/s11904-022-00608-y","DOIUrl":null,"url":null,"abstract":"Purpose of review: Patterns of sexualized drug use, including stimulants (e.g., methamphetamine) and chemsex drugs, are key drivers of HIV incidence among sexual minority men (SMM). Although pre-exposure prophylaxis (PrEP) mitigates HIV risk, there is no consensus regarding the associations of substance use with the PrEP care continuum.Recent findings: SMM who use substances are as likely or more likely to use PrEP. Although SMM who use stimulants experience greater difficulties with daily oral PrEP adherence, some evidence shows that SMM who use stimulants or chemsex drugs may achieve better adherence in the context of recent condomless anal sex. Finally, SMM who use substances may experience greater difficulties with PrEP persistence (including retention in PrEP care). SMM who use stimulants and other substances would benefit from more comprehensive efforts to support PrEP re-uptake, adherence, and persistence, including delivering behavioral interventions, considering event-based dosing, and providing injectable PrEP.","PeriodicalId":10930,"journal":{"name":"Current HIV/AIDS Reports","volume":"19 1","pages":"235-250"},"PeriodicalIF":4.4000,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279195/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current HIV/AIDS Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11904-022-00608-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/6/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Patterns of sexualized drug use, including stimulants (e.g., methamphetamine) and chemsex drugs, are key drivers of HIV incidence among sexual minority men (SMM). Although pre-exposure prophylaxis (PrEP) mitigates HIV risk, there is no consensus regarding the associations of substance use with the PrEP care continuum.

Recent findings: SMM who use substances are as likely or more likely to use PrEP. Although SMM who use stimulants experience greater difficulties with daily oral PrEP adherence, some evidence shows that SMM who use stimulants or chemsex drugs may achieve better adherence in the context of recent condomless anal sex. Finally, SMM who use substances may experience greater difficulties with PrEP persistence (including retention in PrEP care). SMM who use stimulants and other substances would benefit from more comprehensive efforts to support PrEP re-uptake, adherence, and persistence, including delivering behavioral interventions, considering event-based dosing, and providing injectable PrEP.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

用剪刀跑步：对性少数群体男性物质使用和暴露前预防护理持续性的系统评价

审查目的：性化药物使用模式，包括兴奋剂（如甲基苯丙胺）和化学性药物，是性少数男性（SMM）中艾滋病毒感染的主要驱动因素。尽管暴露前预防（PrEP）可降低艾滋病毒风险，但关于药物使用与PrEP护理连续性的关系尚无共识。最近的研究发现：使用药物的SMM同样可能或更可能使用PrEP。尽管使用兴奋剂的SMM每天坚持口服PrEP有更大的困难，但一些证据表明，使用兴奋剂或化学性药物的SMM在最近无套肛交的情况下可能会更好地坚持服用PrEP。最后，使用药物的SMM可能在PrEP持久性方面遇到更大的困难（包括在PrEP护理中滞留）。使用兴奋剂和其他物质的SMM将受益于更全面的努力，支持PrEP的重新摄取，依从性和持久性，包括提供行为干预，考虑基于事件的剂量，并提供注射PrEP。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current HIV/AIDS Reports INFECTIOUS DISEASES-

CiteScore

8.10

自引率

2.20%

发文量

期刊介绍： This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of HIV/AIDS. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as antiretroviral therapies, behavioral aspects of management, and metabolic complications and comorbidity. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.